Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Sara Nadworny"'
Autor:
Victor M. Rivera, Xiaotian Zhu, Kwok-kin Wong, Shengwu Liu, Robert J. Griffin, Johara Chouitar, Michael Fitzgerald, William C. Shakespeare, David Dalgarno, Tim Clackson, Narayana I. Narasimhan, Biplab Das, Stephan G. Zech, Matthew T. Greenfield, Feng Li, Yongbo Hu, Wei-Sheng Huang, Sen Zhang, Yaoyu Ning, Sara Nadworny, Scott D. Wardwell, Shuai Li, Alexandra E. Gould, Theresa E. Baker, Sylvie Vincent, Francois Gonzalvez
Most EGFR exon 20 insertion (EGFRex20ins) driver mutations in non–small cell lung cancer (NSCLC) are insensitive to approved EGFR tyrosine kinase inhibitors (TKI). To address the limitations of existing therapies targeting EGFR-mutated NSCLC, moboc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1233d4a09c246c7e577a052bb61a6464
https://doi.org/10.1158/2159-8290.c.6549370.v1
https://doi.org/10.1158/2159-8290.c.6549370.v1
Autor:
Victor M. Rivera, Xiaotian Zhu, Kwok-kin Wong, Shengwu Liu, Robert J. Griffin, Johara Chouitar, Michael Fitzgerald, William C. Shakespeare, David Dalgarno, Tim Clackson, Narayana I. Narasimhan, Biplab Das, Stephan G. Zech, Matthew T. Greenfield, Feng Li, Yongbo Hu, Wei-Sheng Huang, Sen Zhang, Yaoyu Ning, Sara Nadworny, Scott D. Wardwell, Shuai Li, Alexandra E. Gould, Theresa E. Baker, Sylvie Vincent, Francois Gonzalvez
Supplementary Tables (S1-6) and Figures (S1-6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40b1686b17282cc4afaa22ed044b1306
https://doi.org/10.1158/2159-8290.22540399
https://doi.org/10.1158/2159-8290.22540399
Autor:
Victor M. Rivera, William C. Shakespeare, David Dalgarno, Tim Clackson, Xiaotian Zhu, Juan Miret, Frank Wang, Narayana Narasimhan, Emily Ye, Hyun Gyung Jang, Qurish Mohemmad, Yihan Wang, Dong Zou, Shuangying Liu, Wei-Sheng Huang, Lauren Moran, Lindsey Eichinger, Youngchul Song, David Miller, Scott D. Wardwell, Yaoyu Ning, Jeff Keats, Tianjun Zhou, Sara Nadworny, Rachel Squillace, Rana Anjum, Sen Zhang
Purpose: Non–small cell lung cancers (NSCLCs) harboring ALK gene rearrangements (ALK+) typically become resistant to the first-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) crizotinib through development of secondary r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5126f7a2057f9c47635f6496d280ebf0
https://doi.org/10.1158/1078-0432.c.6525524.v1
https://doi.org/10.1158/1078-0432.c.6525524.v1
Autor:
Victor M. Rivera, William C. Shakespeare, David Dalgarno, Tim Clackson, Xiaotian Zhu, Juan Miret, Frank Wang, Narayana Narasimhan, Emily Ye, Hyun Gyung Jang, Qurish Mohemmad, Yihan Wang, Dong Zou, Shuangying Liu, Wei-Sheng Huang, Lauren Moran, Lindsey Eichinger, Youngchul Song, David Miller, Scott D. Wardwell, Yaoyu Ning, Jeff Keats, Tianjun Zhou, Sara Nadworny, Rachel Squillace, Rana Anjum, Sen Zhang
Supplementary Table 1. Brigatinib in vitro activity (IC50s) in a kinase panel (N=289); Supplementary Figure 1. Chemical structures of brigatinib, crizotinib, ceritinib, and alectinib; Supplementary Figure 2. Brigatinib-mediated inhibition of native o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c6bdb6961073a5b3e650ddfb94203a6
https://doi.org/10.1158/1078-0432.22463789.v1
https://doi.org/10.1158/1078-0432.22463789.v1
Autor:
Wei-Sheng, Huang, Feng, Li, Yongjin, Gong, Yun, Zhang, Willmen, Youngsaye, Yongjin, Xu, Xiaotian, Zhu, Matthew T, Greenfield, Anna, Kohlmann, Paul M, Taslimi, Angela, Toms, Stephan G, Zech, Tianjun, Zhou, Biplab, Das, Hyun G, Jang, Meera, Tugnait, Yihua E, Ye, Francois, Gonzalvez, Theresa E, Baker, Sara, Nadworny, Yaoyu, Ning, Scott D, Wardwell, Sen, Zhang, Alexandra E, Gould, Yongbo, Hu, Weston, Lane, Robert J, Skene, Hua, Zou, Tim, Clackson, Narayana I, Narasimhan, Victor M, Rivera, David C, Dalgarno, William C, Shakespeare
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 80:129084
In the treatment of non-small cell lung cancer (NSCLC), patients harboring exon 20 insertion mutations in the epidermal growth factor receptor (EGFR) gene (EGFR) have few effective therapies because this subset of mutants is generally resistant to mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36257c29b5ae4b54e2d345df53177fd7
https://doi.org/10.1016/j.bmcl.2022.129084
https://doi.org/10.1016/j.bmcl.2022.129084
Autor:
Wei-Sheng Huang, Sara Nadworny, Narayana Narasimhan, Charles J. Eyermann, David C. Dalgarno, Victor M. Rivera, William C. Shakespeare
Publikováno v:
Cancer Research. 82:3342-3342
Introduction: EGFR activating mutations are observed in 10-50% of NSCLC patients and the common mutations (L858R [L] and exon 19 deletions [D]) are initially sensitive to first-, second-, and third-generation EGFR inhibitors (eg erlotinib [1G], afati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b478b2d980afa91a4eec642fa30c3f7
https://doi.org/10.1158/1538-7445.am2022-3342
https://doi.org/10.1158/1538-7445.am2022-3342
Autor:
Francois, Gonzalvez, Sylvie, Vincent, Theresa E, Baker, Alexandra E, Gould, Shuai, Li, Scott D, Wardwell, Sara, Nadworny, Yaoyu, Ning, Sen, Zhang, Wei-Sheng, Huang, Yongbo, Hu, Feng, Li, Matthew T, Greenfield, Stephan G, Zech, Biplab, Das, Narayana I, Narasimhan, Tim, Clackson, David, Dalgarno, William C, Shakespeare, Michael, Fitzgerald, Johara, Chouitar, Robert J, Griffin, Shengwu, Liu, Kwok-Kin, Wong, Xiaotian, Zhu, Victor M, Rivera
Publikováno v:
Cancer discovery. 11(7)
Most
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9a090d0d5999a1e6356828f965f2c661
https://pubmed.ncbi.nlm.nih.gov/34284994
https://pubmed.ncbi.nlm.nih.gov/34284994
Autor:
Lauren Moran, Wei-Sheng Huang, Yaoyu Ning, Dong Zou, Scott Wardwell, Emily Y. Ye, Frank Wang, Rachel M. Squillace, Lindsey W. Eichinger, Victor M. Rivera, Jeff Keats, Sen Zhang, William C. Shakespeare, Yihan Wang, Sara Nadworny, Shuangying Liu, Tianjun Zhou, Youngchul Song, Xiaotian Zhu, Tim Clackson, David Miller, Hyun Gyung Jang, Narayana I. Narasimhan, Rana Anjum, David C. Dalgarno, Qurish K. Mohemmad, Juan J. Miret
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 22(22)
Purpose: Non–small cell lung cancers (NSCLCs) harboring ALK gene rearrangements (ALK+) typically become resistant to the first-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) crizotinib through development of secondary r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a954184cf0503cf7aa96ae269a34c3cb
https://pubmed.ncbi.nlm.nih.gov/27780853
https://pubmed.ncbi.nlm.nih.gov/27780853
Autor:
Biplab Das, Yun Zhang, Theresa E. Baker, Xiaotian Zhu, Emily Y. Ye, Meera Tugnait, Wei-Sheng Huang, Tianjun Zhou, Yongjin Xu, Narayana I. Narasimhan, Yaoyu Ning, Hyun Gyung Jang, William C. Shakespeare, David C. Dalgarno, Paul M. Taslimi, Scott Wardwell, Sen Zhang, Sara Nadworny, Victor M. Rivera, Francois Gonzalvez, Willmen Youngsaye, Anna Kohlmann, Feng Li, Gong Yongjin, Matthew T. Greenfield, Stephan G. Zech
Publikováno v:
Cancer Research. 76:2644-2644
In non-small cell lung cancer (NSCLC), multiple classes of activating mutations have been identified in EGFR and HER2 that vary widely in their sensitivity to available tyrosine kinase inhibitors (TKIs). Erlotinib, gefitinib, and afatinib are approve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd3fc4ce5785604d73f92e73f1327360
https://doi.org/10.1158/1538-7445.am2016-2644
https://doi.org/10.1158/1538-7445.am2016-2644
Autor:
Scott Wardwell, Lindsey W. Eichinger, Biplab Das, Sen Zhang, J. Graeme Hodgson, Sara Nadworny, Victor M. Rivera, Emily Y. Ye
Publikováno v:
Cancer Research. 75:781-781
Background: Disease progression in anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients (pts) treated with the first-generation tyrosine kinase inhibitor (TKI) crizotinib, or the second-generation inhibitors ceritini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be00c45056b3701a755ce367752a3b76
https://doi.org/10.1158/1538-7445.am2015-781
https://doi.org/10.1158/1538-7445.am2015-781